The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 is safe and well-tolerated in healthy volunteers, and markedly reduced…
Articles by José Lopes, PhD
Low levels of an enzyme associated with the rare childhood disorder sialidosis may lead to the development of…
The type 2 diabetes medication metformin suppresses the production of collagen, and induces a switch in lung fibroblasts that…
The U.S. Food and Drug Administration (FDA) will allow the start of a Phase 2 clinical trial of treatment candidate …
Idiopathic pulmonary fibrosis (IPF) oral treatment candidate PLN-74809 can prevent the activation of the pro-fibrotic protein TGF-beta by up…
An idiopathic pulmonary fibrosis (IPF) treatment candidate that mimics a tiny RNA molecule lowered the production of key profibrotic proteins…
The medical advisory board of the Pulmonary Fibrosis Foundation (PFF) strongly cautions patients with pulmonary fibrosis (PF) not…
Novel selective blockers of the NOX4 enzyme could ease oxidative stress and the subsequent development of fibrosis in lungs and…
Vitamin D deficiency in patients with idiopathic pulmonary fibrosis (IPF) is associated with functional and clinical predictors of disease…
A protein called PU.1 plays a central role in the deposition of connective tissue during fibrosis, according to new research.